Rasburicase (Elitek)


  • Tumor Lysis Syndrome (see Tumor Lysis Syndrome, [[Tumor Lysis Syndrome]]): used for cases where uric acid cannot be lowered by other therapies


  • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (see Glucose-6-Phosphate Dehydrogenase Deficiency, [[Glucose-6-Phosphate Dehydrogenase Deficiency]]): as these patients will be unable to break down the hydrogen peroxide end product of the urate oxidase reaction


  • Recombinant Urate Oxidase: catalyzes conversion of uric acid to allantoin (which is soluble)
    • Decreases uric acid within hours


  • IV: 0.2 mg/kg/day

Adverse Effects

Cardiovascular Adverse Effects

Hematologic Adverse Effects

Pulmonary Adverse Effects

Toxicologic Adverse Effects

  • Methemoglobinemia (see Methemoglobinemia, [[Methemoglobinemia]])
    • Patients with low inherited or acquired catalase activity may be at risk for methemoglobinemia after rasburicase administration: due to the formation of hydrogen peroxide
    • Some authors recommend the measurement of catalase activity before administering rasburicase


  • Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. Int J Clin Pharm. 2011 Feb;33(1):58-60. doi: 10.1007/s11096-011-9484-3. Epub 2011 Feb 4 [MEDLINE]